These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23359498)

  • 1. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.
    Li Z; Gakovic M; Ragimbeau J; Eloranta ML; Rönnblom L; Michel F; Pellegrini S
    J Immunol; 2013 Mar; 190(5):2335-44. PubMed ID: 23359498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage.
    Li Z; Rotival M; Patin E; Michel F; Pellegrini S
    PLoS One; 2020; 15(1):e0225289. PubMed ID: 31961910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
    Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
    Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.
    Fuchs S; Kaiser-Labusch P; Bank J; Ammann S; Kolb-Kokocinski A; Edelbusch C; Omran H; Ehl S
    Eur J Immunol; 2016 Nov; 46(11):2639-2649. PubMed ID: 27615517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
    Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
    J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
    Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
    Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The
    Gorman JA; Hundhausen C; Kinsman M; Arkatkar T; Allenspach EJ; Clough C; West SE; Thomas K; Eken A; Khim S; Hale M; Oukka M; Jackson SW; Cerosaletti K; Buckner JH; Rawlings DJ
    Front Immunol; 2019; 10():44. PubMed ID: 30740104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression patterns of three JAK-STAT pathway genes in feather follicle development during chicken embryogenesis.
    Tao Y; Zhou X; Liu Z; Zhang X; Nie Y; Zheng X; Li S; Hu X; Yang G; Zhao Q; Mou C
    Gene Expr Patterns; 2020 Jan; 35():119078. PubMed ID: 31759166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK kinases overexpression promotes in vitro cell transformation.
    Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
    Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Atlantic salmon protein tyrosine kinase Tyk2: molecular cloning, modulation of expression and function.
    Sobhkhez M; Hansen T; Iliev DB; Skjesol A; Jørgensen JB
    Dev Comp Immunol; 2013 Dec; 41(4):553-63. PubMed ID: 23872231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis and impaired IL-23-dependent IFN-γ immunity in humans homozygous for a common
    Boisson-Dupuis S; Ramirez-Alejo N; Li Z; Patin E; Rao G; Kerner G; Lim CK; Krementsov DN; Hernandez N; Ma CS; Zhang Q; Markle J; Martinez-Barricarte R; Payne K; Fisch R; Deswarte C; Halpern J; Bouaziz M; Mulwa J; Sivanesan D; Lazarov T; Naves R; Garcia P; Itan Y; Boisson B; Checchi A; Jabot-Hanin F; Cobat A; Guennoun A; Jackson CC; Pekcan S; Caliskaner Z; Inostroza J; Costa-Carvalho BT; de Albuquerque JAT; Garcia-Ortiz H; Orozco L; Ozcelik T; Abid A; Rhorfi IA; Souhi H; Amrani HN; Zegmout A; Geissmann F; Michnick SW; Muller-Fleckenstein I; Fleckenstein B; Puel A; Ciancanelli MJ; Marr N; Abolhassani H; Balcells ME; Condino-Neto A; Strickler A; Abarca K; Teuscher C; Ochs HD; Reisli I; Sayar EH; El-Baghdadi J; Bustamante J; Hammarström L; Tangye SG; Pellegrini S; Quintana-Murci L; Abel L; Casanova JL
    Sci Immunol; 2018 Dec; 3(30):. PubMed ID: 30578352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial impairment of cytokine responses in Tyk2-deficient mice.
    Karaghiosoff M; Neubauer H; Lassnig C; Kovarik P; Schindler H; Pircher H; McCoy B; Bogdan C; Decker T; Brem G; Pfeffer K; Müller M
    Immunity; 2000 Oct; 13(4):549-60. PubMed ID: 11070173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of rare coding variants in
    Motegi T; Kochi Y; Matsuda K; Kubo M; Yamamoto K; Momozawa Y
    Ann Rheum Dis; 2019 Aug; 78(8):1062-1069. PubMed ID: 31118190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
    Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
    J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.
    Wang F; Barrett JW; Shao Q; Gao X; Dekaban GA; McFadden G
    Virology; 2009 Apr; 387(1):136-46. PubMed ID: 19254804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
    Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
    Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells.
    Kopantzev Y; Heller M; Swaminathan N; Rudikoff S
    Oncogene; 2002 Oct; 21(44):6791-800. PubMed ID: 12360405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
    Jensen LT; Attfield KE; Feldmann M; Fugger L
    EBioMedicine; 2023 Nov; 97():104840. PubMed ID: 37863021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of IL-13- and IL-4-induced signaling in EBV-immortalized human B cells.
    Murata T; Puri RK
    Cell Immunol; 1997 Jan; 175(1):33-40. PubMed ID: 9015186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.